SCHEMBL5653615

SCHEMBL5653615

CCN(CC)CCCNC(=O)c1ccc(-c2nc3cc4ccccc4cc3[nH]2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.46
TP53 P04637 2/20 0.45
GAA P10253 2/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TSHR P16473 1/20 0.44
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GLA P06280 1/20 0.43
USP7 Q93009 2/20 0.43
MAPT P10636 2/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
NSD2 O96028 1/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650314 0.90 HDAC6 (0.47) HDAC6TP53GAAHTTSMN1; SMN2
SCHEMBL5649255 0.89 PRSS12 (0.50) HDAC6TP53GAAHTTSMN1; SMN2
SCHEMBL5653023 0.88 PRMT5 (0.50) HDAC6GAAHTTKMT2AOPRM1
SCHEMBL5651653 0.88 HTT (0.49) HDAC6TP53GAAHTTSMN1; SMN2
SCHEMBL5651662 0.88 HTT (0.49) HDAC6TP53GAAHTTSMN1; SMN2
SCHEMBL5653304 0.88 HDAC6 (0.47) HDAC6TP53GAAHTTSMN1; SMN2
SCHEMBL5649315 0.88 HDAC6 (0.54) HDAC6TSHRALDH1A1MEN1NSD2
SCHEMBL5651518 0.87 FLT3 (0.53) KDM4EHSD17B10MMP2MMP9MMP8
SCHEMBL5648694 0.86 TP53 (0.47) HDAC6TP53GAAHTTSMN1; SMN2
SCHEMBL5648685 0.86 TP53 (0.47) HDAC6TP53GAAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 HDAC6 537/4885TP53 4051/4885GAA 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.